Basic and clinical studies on cefetamet pivoxil

Yuei Irabu; Hiroshi Fukuhara; Hiroaki Nakamura; Hiroshi Kaneshima; Katsuyoshi Shimoji; Keizo Kitsukawa; Yoshiteru Shigeno; Atsushi Saito; Shinko Taira; Isamu Nakasone; Nobuchika Kusano; Seitetsu Hokama

doi:10.11250/chemotherapy1953.38.Supplement1_193

Basic and clinical studies on cefetamet pivoxil

Yuei Irabu, Hiroshi Fukuhara, Hiroaki Nakamura, Hiroshi Kaneshima, Katsuyoshi Shimoji, Keizo Kitsukawa, Yoshiteru Shigeno, Atsushi Saito, Shinko Taira, Isamu Nakasone, Nobuchika Kusano, Seitetsu Hokama

Research output: Contribution to journal › Article › peer-review

Abstract

We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin, with the following results. 1) Antimicrobial activity : the minimum inhibitory concentrations (MICs) of cefetamet (CEMT) against 338 clinically isolated strains were determined and compared with those of cefteram, cefixime, cefaclor, cefotiam, ampicillin, using a Dynatech MIC-2000 system. CEMT had wide-spectrum antimicrobial activity against these isolated strains, except Pseudomonas aeruginosa, methicillin sensitive Staphylococcus aureus and methicillin resistant S. aureus. 2) Clinical efficacy : CEMT-PI at 500 or 1,000 mg/day was given to 2 patients with bacterial pneumonia, 2 with bacterial pneumonia complicated with chronic bronchitis, 5 with chronic bronchitis and 1 with diffuse panbronchiolitis for 4-14 days. Clinical response was excellent in 2 patients, good in 6, fair in 1 and poor in 1, and the overall clinical efficacy was 80%. 3) Bacteriological efficacy : one strain of Haemophilus influenzae was eradicated, one strain of Klebsiella pneumoniae changed to Proteus vulgaris, and one strain of Streptococcus pneumoniae persisted. 4) Safety : no side effects and altered laboratory findings were observed.

Original language	English
Pages (from-to)	193-197
Number of pages	5
Journal	CHEMOTHERAPY
Volume	38
DOIs	https://doi.org/10.11250/chemotherapy1953.38.Supplement1_193
Publication status	Published - 1990
Externally published	Yes

Keywords

CEMT-PI
Cefetamet pivoxil

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.11250/chemotherapy1953.38.Supplement1_193

Fingerprint Dive into the research topics of 'Basic and clinical studies on cefetamet pivoxil'. Together they form a unique fingerprint.

Cite this

Basic and clinical studies on cefetamet pivoxil. / Irabu, Yuei; Fukuhara, Hiroshi; Nakamura, Hiroaki; Kaneshima, Hiroshi; Shimoji, Katsuyoshi; Kitsukawa, Keizo; Shigeno, Yoshiteru; Saito, Atsushi; Taira, Shinko; Nakasone, Isamu; Kusano, Nobuchika; Hokama, Seitetsu.

In: CHEMOTHERAPY, Vol. 38, 1990, p. 193-197.

Research output: Contribution to journal › Article › peer-review

@article{cb831ab79c9840d5b4938f1e49dd37cf,

title = "Basic and clinical studies on cefetamet pivoxil",

abstract = "We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin, with the following results. 1) Antimicrobial activity : the minimum inhibitory concentrations (MICs) of cefetamet (CEMT) against 338 clinically isolated strains were determined and compared with those of cefteram, cefixime, cefaclor, cefotiam, ampicillin, using a Dynatech MIC-2000 system. CEMT had wide-spectrum antimicrobial activity against these isolated strains, except Pseudomonas aeruginosa, methicillin sensitive Staphylococcus aureus and methicillin resistant S. aureus. 2) Clinical efficacy : CEMT-PI at 500 or 1,000 mg/day was given to 2 patients with bacterial pneumonia, 2 with bacterial pneumonia complicated with chronic bronchitis, 5 with chronic bronchitis and 1 with diffuse panbronchiolitis for 4-14 days. Clinical response was excellent in 2 patients, good in 6, fair in 1 and poor in 1, and the overall clinical efficacy was 80%. 3) Bacteriological efficacy : one strain of Haemophilus influenzae was eradicated, one strain of Klebsiella pneumoniae changed to Proteus vulgaris, and one strain of Streptococcus pneumoniae persisted. 4) Safety : no side effects and altered laboratory findings were observed.",

keywords = "CEMT-PI, Cefetamet pivoxil",

author = "Yuei Irabu and Hiroshi Fukuhara and Hiroaki Nakamura and Hiroshi Kaneshima and Katsuyoshi Shimoji and Keizo Kitsukawa and Yoshiteru Shigeno and Atsushi Saito and Shinko Taira and Isamu Nakasone and Nobuchika Kusano and Seitetsu Hokama",

year = "1990",

doi = "10.11250/chemotherapy1953.38.Supplement1_193",

language = "English",

volume = "38",

pages = "193--197",

journal = "Chemotherapy",

issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies on cefetamet pivoxil

AU - Irabu, Yuei

AU - Fukuhara, Hiroshi

AU - Nakamura, Hiroaki

AU - Kaneshima, Hiroshi

AU - Shimoji, Katsuyoshi

AU - Kitsukawa, Keizo

AU - Shigeno, Yoshiteru

AU - Saito, Atsushi

AU - Taira, Shinko

AU - Nakasone, Isamu

AU - Kusano, Nobuchika

AU - Hokama, Seitetsu

PY - 1990

Y1 - 1990

N2 - We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin, with the following results. 1) Antimicrobial activity : the minimum inhibitory concentrations (MICs) of cefetamet (CEMT) against 338 clinically isolated strains were determined and compared with those of cefteram, cefixime, cefaclor, cefotiam, ampicillin, using a Dynatech MIC-2000 system. CEMT had wide-spectrum antimicrobial activity against these isolated strains, except Pseudomonas aeruginosa, methicillin sensitive Staphylococcus aureus and methicillin resistant S. aureus. 2) Clinical efficacy : CEMT-PI at 500 or 1,000 mg/day was given to 2 patients with bacterial pneumonia, 2 with bacterial pneumonia complicated with chronic bronchitis, 5 with chronic bronchitis and 1 with diffuse panbronchiolitis for 4-14 days. Clinical response was excellent in 2 patients, good in 6, fair in 1 and poor in 1, and the overall clinical efficacy was 80%. 3) Bacteriological efficacy : one strain of Haemophilus influenzae was eradicated, one strain of Klebsiella pneumoniae changed to Proteus vulgaris, and one strain of Streptococcus pneumoniae persisted. 4) Safety : no side effects and altered laboratory findings were observed.

AB - We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin, with the following results. 1) Antimicrobial activity : the minimum inhibitory concentrations (MICs) of cefetamet (CEMT) against 338 clinically isolated strains were determined and compared with those of cefteram, cefixime, cefaclor, cefotiam, ampicillin, using a Dynatech MIC-2000 system. CEMT had wide-spectrum antimicrobial activity against these isolated strains, except Pseudomonas aeruginosa, methicillin sensitive Staphylococcus aureus and methicillin resistant S. aureus. 2) Clinical efficacy : CEMT-PI at 500 or 1,000 mg/day was given to 2 patients with bacterial pneumonia, 2 with bacterial pneumonia complicated with chronic bronchitis, 5 with chronic bronchitis and 1 with diffuse panbronchiolitis for 4-14 days. Clinical response was excellent in 2 patients, good in 6, fair in 1 and poor in 1, and the overall clinical efficacy was 80%. 3) Bacteriological efficacy : one strain of Haemophilus influenzae was eradicated, one strain of Klebsiella pneumoniae changed to Proteus vulgaris, and one strain of Streptococcus pneumoniae persisted. 4) Safety : no side effects and altered laboratory findings were observed.

KW - CEMT-PI

KW - Cefetamet pivoxil

UR - http://www.scopus.com/inward/record.url?scp=0025641121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025641121&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.38.Supplement1_193

DO - 10.11250/chemotherapy1953.38.Supplement1_193

M3 - Article

AN - SCOPUS:0025641121

VL - 38

SP - 193

EP - 197

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -

Basic and clinical studies on cefetamet pivoxil

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this